8TLY
 
 | |
8TUK
 | | Alvinella ASCC1 KH and Phosphodiesterase/Ligase Domain | | Descriptor: | 1,2-ETHANEDIOL, Activating signal cointegrator 1 complex subunit 1, IMIDAZOLE | | Authors: | Tsutakawa, S.E, Tainer, J.A, Arvai, A.S, Chinnam, N.B. | | Deposit date: | 2023-08-16 | | Release date: | 2024-07-10 | | Method: | X-RAY DIFFRACTION (1.15 Å) | | Cite: | ASCC1 structures and bioinformatics reveal a novel helix-clasp-helix RNA-binding motif linked to a two-histidine phosphodiesterase.
J.Biol.Chem., 300, 2024
|
|
7OC9
 | |
8PH4
 | | Co-Crystal structure of the SARS-CoV2 main protease Nsp5 with an Uracil-carrying X77-like inhibitor | | Descriptor: | 3C-like proteinase nsp5, DIMETHYL SULFOXIDE, MALONATE ION, ... | | Authors: | Barthel, T, Altincekic, N, Jores, N, Wollenhaupt, J, Weiss, M.S, Schwalbe, H. | | Deposit date: | 2023-06-18 | | Release date: | 2024-01-31 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.69 Å) | | Cite: | Targeting the Main Protease (M pro , nsp5) by Growth of Fragment Scaffolds Exploiting Structure-Based Methodologies.
Acs Chem.Biol., 19, 2024
|
|
7ZFE
 | | SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1 | | Descriptor: | Nanobody C1, Omi-32 heavy chain, Omi-32 light chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.25 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFD
 | | SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab | | Descriptor: | Omi-25 heavy chain, Omi-25 light chain, Spike protein S1 | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.39 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFF
 | | Omi-42 Fab | | Descriptor: | GLYCEROL, Omi-42 Heavy chain, Omi-42 light chain | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.32 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF6
 | | Omi-12 Fab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CITRIC ACID, GLYCEROL, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.21 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFC
 | | SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs | | Descriptor: | Nanobody C1, Omi-18 heavy chain, Omi-18 light chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.24 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF8
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab | | Descriptor: | COVOX-150 heavy chain, COVOX-150 light chain, Spike protein S1 | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.95 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFB
 | | SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Nanobody C1, Omi-18 heavy chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.08 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF9
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, COVOX-150 heavy chain, COVOX-150 light chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.25 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF7
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike protein S1, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.46 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF5
 | | SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs | | Descriptor: | Beta-54 heavy chain, Beta-54 light chain, Omi-12 heavy chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (5.32 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF3
 | | SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs | | Descriptor: | EY6A heavy chain, EY6A light chain, GLYCEROL, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.15 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF4
 | | SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 | | Descriptor: | Nanobody F2, Omi-9 heavy chain, Omi-9 light chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-08 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (4.18 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFA
 | | SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs | | Descriptor: | COVOX-150 heavy chain, COVOX-150 light chain, Omi-6 heavy chain, ... | | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | Deposit date: | 2022-04-01 | | Release date: | 2022-06-29 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (4.24 Å) | | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ORB
 | | Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs | | Descriptor: | 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Zhou, D, Ren, J, Stuart, D.I. | | Deposit date: | 2021-06-04 | | Release date: | 2021-07-07 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell, 184, 2021
|
|
7OR9
 | | Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, COVOX-222 Fab heavy chain, ... | | Authors: | Zhou, D, Ren, J, Stuart, D.I. | | Deposit date: | 2021-06-04 | | Release date: | 2021-07-07 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.34 Å) | | Cite: | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell, 184, 2021
|
|
7ORA
 | | Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, COVOX-253 Fab heavy chain, ... | | Authors: | Zhou, D, Ren, J, Stuart, D.I. | | Deposit date: | 2021-06-04 | | Release date: | 2021-07-07 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell, 184, 2021
|
|
1FVF
 | |
1FVH
 | |
6NF0
 | | Nocturnin with bound NADPH substrate | | Descriptor: | CALCIUM ION, NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, Nocturnin | | Authors: | Estrella, M.A, Du, J, Korennykh, A. | | Deposit date: | 2018-12-18 | | Release date: | 2019-05-01 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | The metabolites NADP+and NADPH are the targets of the circadian protein Nocturnin (Curled).
Nat Commun, 10, 2019
|
|
7DZW
 | | Apo spike protein from SARS-CoV2 | | Descriptor: | Spike glycoprotein | | Authors: | Liu, Y, Soh, W.T, Li, S, Kishikawa, J, Hirose, M, Kato, T, Standley, D, Okada, M, Arase, H. | | Deposit date: | 2021-01-26 | | Release date: | 2021-06-02 | | Last modified: | 2024-03-27 | | Method: | ELECTRON MICROSCOPY (3.45 Å) | | Cite: | An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell, 184, 2021
|
|
7DZX
 | | Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2 | | Descriptor: | Fab Heavy chain of enhancing antibody, Fab light chain of enhancing antibody, Spike glycoprotein | | Authors: | Liu, Y, Soh, W.T, Li, S, Kishikawa, J, Hirose, M, Kato, T, Standley, D, Okada, M, Arase, H. | | Deposit date: | 2021-01-26 | | Release date: | 2021-06-02 | | Last modified: | 2024-03-27 | | Method: | ELECTRON MICROSCOPY (3.53 Å) | | Cite: | An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell, 184, 2021
|
|
